Anton Gomez-Escolar
The Psychedelic Reawakening
How Psilocybin, Mdma, Ketamine, Lsd, and Dmt Are Changing Lives
22,99 €
inkl. MwSt.
Versandfertig in über 4 Wochen
11 °P sammeln
Anton Gomez-Escolar
The Psychedelic Reawakening
How Psilocybin, Mdma, Ketamine, Lsd, and Dmt Are Changing Lives
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Explores the benefits, risks, and growing acceptance of modern psychedelic therapy
Andere Kunden interessierten sich auch für
- Michael PollanHow to Change Your Mind11,99 €
- Franklin Benjamin GottschalkStatic Electricity, X-ray and Electro-vibration: Their Therapeutic Application20,99 €
- The Chemist and Druggist [electronic Resource]; Vol. 32 (28 Jan. 1888)25,99 €
- AnonymousThe Pharmacopoeia of the United States of America: 182024,99 €
- The Chemist and Druggist [electronic Resource]; Vol. 93, no. 12 = no. 2121 (18 Sept. 1920)20,99 €
- The Chemist and Druggist [electronic Resource]; Vol. 51, no. 9 (28 Aug. 1897)19,99 €
- The Chemist and Druggist [electronic Resource]; Vol. 37 (29 Nov. 1890)17,99 €
-
-
-
Explores the benefits, risks, and growing acceptance of modern psychedelic therapy
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Inner Traditions/Bear & Company
- 2nd Edition, New of Essential Guide to the Psychedelic Renaissance edition
- Seitenzahl: 320
- Erscheinungstermin: 11. März 2025
- Englisch
- Abmessung: 226mm x 150mm x 20mm
- Gewicht: 522g
- ISBN-13: 9798888500026
- Artikelnr.: 71566922
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
- Verlag: Inner Traditions/Bear & Company
- 2nd Edition, New of Essential Guide to the Psychedelic Renaissance edition
- Seitenzahl: 320
- Erscheinungstermin: 11. März 2025
- Englisch
- Abmessung: 226mm x 150mm x 20mm
- Gewicht: 522g
- ISBN-13: 9798888500026
- Artikelnr.: 71566922
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
Anton Gomez-Escolar, MSc, MPH, MIR, is a psychopharmacologist who works on psychedelic research, drug education, and harm reduction. He is the founder of Drogopedia, has worked at organizations like Energy Control and the European Union Drugs Agency (EUDA), and has presented on psychedelics at several international forums, including the European Parliament and the United Nations. He is a member of the UNAD Global Drug Policy Commission, and cofounder and board member of the Spanish Society of Psychedelic Medicine (SEMPsi), the INAWE Foundation (for psychedelic science), and the Psychedelic Society of Madrid. He lives in Madrid.
FOREWORD
by Rick Doblin, Ph.D.
Preface
1 Basic Concepts of Neuroscience and
Neuropharmacology
The Brain and Central Nervous System
Neurons, Synapses, Neurotransmitters, and
Neuroreceptors
Neuropharmacology
2 Introduction to Psychoactive Substances
Talking about Psychoactive Substances
Types of Psychoactive Substances
Stimulants
Depressants
Opioids
Cannabinoids
Empathogens/Entactogens
Dissociatives
Psychedelics
3 A History of Psychedelics in the West
Pre-LSD
Post-LSD
MDMA
After the Ban
4 The Psychedelic Renaissance
Ongoing Psychedelics Research
Social and Cultural Contexts
The Rise of a New Industry
5 How Psychedelics Work
Mechanisms at the Neuroreceptor Level
Mechanisms at the Brain Level
How Does the Brain Work? Hierarchical Predictive Coding
How Do Psychedelics Affect Our Brain Function?
What Happens at the Psychological Level?
Why Do We Have 5-HT2a Receptors and
Psychedelic Experiences?
How Can Psychedelics Help with Mental Health
Disorders or Other Maladaptive Conditions?
6 The Present and Future of Clinical Research
with Psychedelic Drugs
Psychedelic-Assisted Psychotherapy
Post-Traumatic Stress Disorder (PTSD)
Depression and Anxiety
Addictions
Neurodegenerative Diseases, Long COVID,
and Neurorehabiliation
Behavior Change
Couples Therapy and Conflict Resolution
Microdosing
Other Lines of Research for Possible Future Applications
7 The Applications, Effects, Dosages, and
Risks of Different Psychedelic Substances
Psilocybin (“Magic Mushrooms”)
LSD (“Acid”)
DMT/Ayahuasca
5-MeO-DMT (“Toad”)
Mescaline (“Cactus”)
Ibogaine
MDMA (“Ecstasy”)
Ketamine
8 Psychedelic Risks and Harm Reduction Strategies
Risks Related to Substance (Drug)
Dosage, Frequency of Consumption, and Tolerance
Purity and Adulteration
Routes of Administration
Mixtures and Combinations
Risks Related to Person and Context (Set and Setting)
Minimizing Risks Related to the Set
Minimizing Risks Related to the Setting
Managing “Bad Trips” and other Psychedelic Emergencies
9 Conclusions: Looking to the Future
APPENDIX I
Psychedelic Resources
APPENDIX II
The Legal Status of Psychedelic Drugs
around the World
APPENDIX III
Glossary
Index
by Rick Doblin, Ph.D.
Preface
1 Basic Concepts of Neuroscience and
Neuropharmacology
The Brain and Central Nervous System
Neurons, Synapses, Neurotransmitters, and
Neuroreceptors
Neuropharmacology
2 Introduction to Psychoactive Substances
Talking about Psychoactive Substances
Types of Psychoactive Substances
Stimulants
Depressants
Opioids
Cannabinoids
Empathogens/Entactogens
Dissociatives
Psychedelics
3 A History of Psychedelics in the West
Pre-LSD
Post-LSD
MDMA
After the Ban
4 The Psychedelic Renaissance
Ongoing Psychedelics Research
Social and Cultural Contexts
The Rise of a New Industry
5 How Psychedelics Work
Mechanisms at the Neuroreceptor Level
Mechanisms at the Brain Level
How Does the Brain Work? Hierarchical Predictive Coding
How Do Psychedelics Affect Our Brain Function?
What Happens at the Psychological Level?
Why Do We Have 5-HT2a Receptors and
Psychedelic Experiences?
How Can Psychedelics Help with Mental Health
Disorders or Other Maladaptive Conditions?
6 The Present and Future of Clinical Research
with Psychedelic Drugs
Psychedelic-Assisted Psychotherapy
Post-Traumatic Stress Disorder (PTSD)
Depression and Anxiety
Addictions
Neurodegenerative Diseases, Long COVID,
and Neurorehabiliation
Behavior Change
Couples Therapy and Conflict Resolution
Microdosing
Other Lines of Research for Possible Future Applications
7 The Applications, Effects, Dosages, and
Risks of Different Psychedelic Substances
Psilocybin (“Magic Mushrooms”)
LSD (“Acid”)
DMT/Ayahuasca
5-MeO-DMT (“Toad”)
Mescaline (“Cactus”)
Ibogaine
MDMA (“Ecstasy”)
Ketamine
8 Psychedelic Risks and Harm Reduction Strategies
Risks Related to Substance (Drug)
Dosage, Frequency of Consumption, and Tolerance
Purity and Adulteration
Routes of Administration
Mixtures and Combinations
Risks Related to Person and Context (Set and Setting)
Minimizing Risks Related to the Set
Minimizing Risks Related to the Setting
Managing “Bad Trips” and other Psychedelic Emergencies
9 Conclusions: Looking to the Future
APPENDIX I
Psychedelic Resources
APPENDIX II
The Legal Status of Psychedelic Drugs
around the World
APPENDIX III
Glossary
Index
FOREWORD
by Rick Doblin, Ph.D.
Preface
1 Basic Concepts of Neuroscience and
Neuropharmacology
The Brain and Central Nervous System
Neurons, Synapses, Neurotransmitters, and
Neuroreceptors
Neuropharmacology
2 Introduction to Psychoactive Substances
Talking about Psychoactive Substances
Types of Psychoactive Substances
Stimulants
Depressants
Opioids
Cannabinoids
Empathogens/Entactogens
Dissociatives
Psychedelics
3 A History of Psychedelics in the West
Pre-LSD
Post-LSD
MDMA
After the Ban
4 The Psychedelic Renaissance
Ongoing Psychedelics Research
Social and Cultural Contexts
The Rise of a New Industry
5 How Psychedelics Work
Mechanisms at the Neuroreceptor Level
Mechanisms at the Brain Level
How Does the Brain Work? Hierarchical Predictive Coding
How Do Psychedelics Affect Our Brain Function?
What Happens at the Psychological Level?
Why Do We Have 5-HT2a Receptors and
Psychedelic Experiences?
How Can Psychedelics Help with Mental Health
Disorders or Other Maladaptive Conditions?
6 The Present and Future of Clinical Research
with Psychedelic Drugs
Psychedelic-Assisted Psychotherapy
Post-Traumatic Stress Disorder (PTSD)
Depression and Anxiety
Addictions
Neurodegenerative Diseases, Long COVID,
and Neurorehabiliation
Behavior Change
Couples Therapy and Conflict Resolution
Microdosing
Other Lines of Research for Possible Future Applications
7 The Applications, Effects, Dosages, and
Risks of Different Psychedelic Substances
Psilocybin (“Magic Mushrooms”)
LSD (“Acid”)
DMT/Ayahuasca
5-MeO-DMT (“Toad”)
Mescaline (“Cactus”)
Ibogaine
MDMA (“Ecstasy”)
Ketamine
8 Psychedelic Risks and Harm Reduction Strategies
Risks Related to Substance (Drug)
Dosage, Frequency of Consumption, and Tolerance
Purity and Adulteration
Routes of Administration
Mixtures and Combinations
Risks Related to Person and Context (Set and Setting)
Minimizing Risks Related to the Set
Minimizing Risks Related to the Setting
Managing “Bad Trips” and other Psychedelic Emergencies
9 Conclusions: Looking to the Future
APPENDIX I
Psychedelic Resources
APPENDIX II
The Legal Status of Psychedelic Drugs
around the World
APPENDIX III
Glossary
Index
by Rick Doblin, Ph.D.
Preface
1 Basic Concepts of Neuroscience and
Neuropharmacology
The Brain and Central Nervous System
Neurons, Synapses, Neurotransmitters, and
Neuroreceptors
Neuropharmacology
2 Introduction to Psychoactive Substances
Talking about Psychoactive Substances
Types of Psychoactive Substances
Stimulants
Depressants
Opioids
Cannabinoids
Empathogens/Entactogens
Dissociatives
Psychedelics
3 A History of Psychedelics in the West
Pre-LSD
Post-LSD
MDMA
After the Ban
4 The Psychedelic Renaissance
Ongoing Psychedelics Research
Social and Cultural Contexts
The Rise of a New Industry
5 How Psychedelics Work
Mechanisms at the Neuroreceptor Level
Mechanisms at the Brain Level
How Does the Brain Work? Hierarchical Predictive Coding
How Do Psychedelics Affect Our Brain Function?
What Happens at the Psychological Level?
Why Do We Have 5-HT2a Receptors and
Psychedelic Experiences?
How Can Psychedelics Help with Mental Health
Disorders or Other Maladaptive Conditions?
6 The Present and Future of Clinical Research
with Psychedelic Drugs
Psychedelic-Assisted Psychotherapy
Post-Traumatic Stress Disorder (PTSD)
Depression and Anxiety
Addictions
Neurodegenerative Diseases, Long COVID,
and Neurorehabiliation
Behavior Change
Couples Therapy and Conflict Resolution
Microdosing
Other Lines of Research for Possible Future Applications
7 The Applications, Effects, Dosages, and
Risks of Different Psychedelic Substances
Psilocybin (“Magic Mushrooms”)
LSD (“Acid”)
DMT/Ayahuasca
5-MeO-DMT (“Toad”)
Mescaline (“Cactus”)
Ibogaine
MDMA (“Ecstasy”)
Ketamine
8 Psychedelic Risks and Harm Reduction Strategies
Risks Related to Substance (Drug)
Dosage, Frequency of Consumption, and Tolerance
Purity and Adulteration
Routes of Administration
Mixtures and Combinations
Risks Related to Person and Context (Set and Setting)
Minimizing Risks Related to the Set
Minimizing Risks Related to the Setting
Managing “Bad Trips” and other Psychedelic Emergencies
9 Conclusions: Looking to the Future
APPENDIX I
Psychedelic Resources
APPENDIX II
The Legal Status of Psychedelic Drugs
around the World
APPENDIX III
Glossary
Index